Specifically, inhibition of estrogen signaling was accompanied by reformatting the TME toward a pro-tumor phenotype evidenced by upregulated expression of Il6, Tgfb, and Il17 among other pro-tumor immune markers. The gene discussed is TGFB1; the disease is neoplasm.